Study summary · research use only
[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this rat study, the authors examined the peptide Livagen (Lys-Glu-Asp-Ala) on digestive-enzyme activity in the gastrointestinal tract and other organs across ages. They report that Livagen is weakly hydrolyzed, is not appreciably broken down by small-intestinal peptide hydrolases, and in vitro reduced glycil-L-leucine dipeptidase activity in the small intestine by 50%. After two weeks of oral Livagen, digestive-enzyme activity decreased in young rats but increased in old rats, with enzyme activity in old rats approaching that of young control animals in most cases.
Abstract
It is stated that Livagen (Lys-Glu-Asp-Ala) is a weakly hydrolyzed peptide. Peptide hydrolases of small intestine do not hydrolyze Livagen even to a small extent. Under in vitro conditions Livagen reduces glycil-L-leucinedipeptidase activity in small intestine by 50%. After two weeks of Livagen administration per os in rats the digestive enzymes activity in young animals reduces, while in old animals it increases. It should be mentioned that the activity of enzymes in old rats after Livagen administration in the majority of cases approaches to the level of the activity in young animals of control group.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.